Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021
May 07 2021 - 10:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing, today announced that it will report fiscal 2021
second quarter financial results after market close on Thursday,
May 13, 2021. The Company’s management will discuss the results
during a conference call and simultaneous webcast at 4:30 p.m. ET
that same day. Presentation slides will also be posted to the ‘IR
Calendar’ section of the Company’s corporate website and embedded
into the live webcast.
Conference Call and Webcast Information
- Live
Date:
Thursday, May 13, 2021, at 4:30 p.m.
Eastern Daylight Time
Dial in:
844-887-9402
412-317-6798 (international)
Hosts:
Dr. James A. Hayward, chairman, president,
and CEO
Beth Jantzen, chief financial officer
Webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=YaMBr3pT
Conference Call and Webcast Information
- Replay
A telephonic replay of the conference call will be available for
one week beginning one hour after the end of the live conference
call.
Dial in:
877-344-7529
412-317-0088 (international)
Access Code: 10154121
Webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=YaMBr3pT
Availability:
Telephonic replay: until Thursday, May 20,
2021; webcast replay: 1 year
The webcast and accompanying PowerPoint presentation will also
be archived on the ‘IR Calendar’ page listed under the Investor
Relations drop-down menu on the Company’s website.
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies. Applied DNA has also established a
COVID-19 diagnostic and testing offering that is in the early
stages of commercialization and is grounded in the Company’s deep
expertise in DNA.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include Gov/Mil, textiles,
pharmaceuticals and nutraceuticals, and cannabis, among others.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210507005087/en/
Investor contact: Sanjay M. Hurry, Applied DNA Sciences,
917-733-5573, sanjay.hurry@adnas.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024